secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clearside Biomedical, Inc. (CLSDQ)
CIK:        0001539029
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0000950170-23-042410
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clearside Q2 net loss $9.1M; Phase 2b ODYSSEY enrollment underway, topline Q3 2024
--------------------------------------------------------------------------------

- Net loss $9.1M ($0.15/share) vs $7.8M ($0.13) prior year; cash $35.0M, operations funded into Q3 2024.
- Phase 2b ODYSSEY trial for CLS-AX in wet AMD actively enrolling at ~30 U.S. sites; topline data expected Q3 2024.
- Partner Arctic Vision's NDA accepted in Australia for Arcatus (suprachoroidal treatment of uveitic macular edema).
- R&D expenses $4.9M (down from $5.4M); license revenue $1.0M (up from $0.4M).
- Board Chair changed to Clay B. Thorp; Scientific Advisory Board expanded with three new members.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1539029/000095017023042410/0000950170-23-042410-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1539029/000095017023042410/clsd-20230814.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-042410

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer